SIRRIS
Bioprinting: markets and opportunities
Grégory Nolens
QED –AM in Medical – November 4th 2014
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 2
130 experts & high-tech infrastructure
Collective centre of the technology industry • Non profit organization • Industry owned
4,700 industrial interventions (advice, projects, services) •within 1,700 different companies •whose 75% are SME’s •24M EUR turnover
Mission
“Increase the competitiveness of companies of the Agoria sectors through technological innovations”
3
Additive Manufacturing technologies @ Sirris
SIRRIS – One of the largest machine park in EU
• 16 engineers and technicians
• Two locations: Liège (11 p.) and Charleroi (5 p.)
Rapid Prototyping / Tooling / Manufacturing
• Stereolithography (normal & hi-res)
• Paste polymerization for ceramics and metals (Optoform)
• 3D Printing of plaster and metal powder
• Laser sintering of polymeric powder (PA,…): P360 – P390
• Objet Connex 500: bi-material
• Laser sintering of metal powder (parts and mould inserts)
• Electron Beam Melting (Arcam A2)
• 3D Printing of wax (Thermojet)
• Vacuum Casting of Alu, Bronze, Zamak
• Laser Cladding (EasyClad)
• Selective Laser melting (MTT)
• Mcor - paper
• Bi-material FDM system
© sirris 2014 Charleroi | www.sirris.be | [email protected] | 04/11/2014
04/11/2014 4
CASE STUDIES @ SIRRIS
Leading applications of AM in biomedical:
• Personalized/complex devices
• Surgery tools
• In vitro Testing tools
• Communication tools
•Physician to Physician/Patient
•Student/education
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
5
Personalized implants
© sirris 2014 Charleroi | www.sirris.be | [email protected] | 04/11/2014
Poukens – Xilloc - Sirris
6 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 04/11/2014
Newly designed implants – lattice porous structures
Finger prosthesis [UMons, Faculté Polytechnique] Cranial porous implant [SIRRIS-ADD]
04/11/2014 7
Complex implants – mass production
Spinal case studies in ceramic
• Porous scaffolds for Spine surgery
• In vivo testing for bone integration
• France - Belgium collaboration Tech transfer
[Sirris ADD]
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
04/11/2014 8
Surgery tools – custom cutting
CENG
[VISYOS] [VISYOS]
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
20-70% surgery time reduction
04/11/2014 9
Surgery tools – custom cutting
CENG
Surgical Cutting Templates – reimbursement problem
Surgical guides not reimbursed, but facts are:
- 1 min. in surgical theatre (estimated): 60€
- Mean of orthopedic surgery duration: 5-12h (18k-44k€)
- Surgical guide can reduce: 20-70% of the duration (TBC)
- Surgical guide cost: 50-300€
- Economy: estimated 3-30k€/surgery
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
10
Testing tools
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
Flexible device for in vitro studies (e.g. arteries)
04/11/2014
11
Communication/education tools
© sirris 2014 Charleroi | www.sirris.be | [email protected] | 04/11/2014
[Sirris ADD] [Sirris ADD] [Sirris ADD]
12 © sirris 2014 Charleroi | www.sirris.be | [email protected] | CENG 04/11/2014
The future of bio-manufacturing…not so far away!
13 © sirris 2014 Charleroi | www.sirris.be | [email protected] | CENG 04/11/2014
The future of bio-manufacturing…not so far away!
Anthony Atala – TED – March 2011
14
process of printing biologically relevant materials (such as cells,
tissues, and biodegradable biomaterials) that will accomplish
one or more biological functions
What’s Bioprinting
04/11/2014
+
cells
Bio-glue
3D machine
Tissues Scaffolds
+ cells
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
04/11/2014 15
Bioprinting – an emerging technology
Bioprinting place in emerging technologies, from the Hype Cycle for Emerging
Technologies 2014- Gartner
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 16
Printing cells and biomaterials
Printing cells and biomaterials
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 17
EnvisionTech, RegenHU (CH), GESIM (DE), Regenovo
(China)…
3D Bioprinting solutions – customized machines
Printing Cells? Reality
Lot of barriers to raise
Technical, ethical, validation time, standards,…
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 18
Bioprinting strategy @ SIRRIS
Step by step approach:
Target most promising and nearest markets
Combine existing knowledge to succeed faster
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 19
20
Market approach interest for companies?
04/11/2014
• Applications:
1. Drug/Cosmetic discovery & Assays
2. Cell therapy + Tissue Engineering
3. Bioproduction
4. In vitro diagnostic & research
5. Food
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
21
Drug/Cosmetic Discovery and Assays
04/11/2014
• Facts: Drug Discovery and Assays
• 90-95% of drugs approved on animal (mouse, rabbit, etc.), was not
for human lot of money lost, ethic problem
• Animal use: 10-100 Mio in US/year
• European Comission banning: FULL on cosmetic (2013), next
pharma ?
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
22
Drug Discovery and Assays
04/11/2014
• Applications:
• Drug screening w/o animal
& less deviations
Drug X
Disease tissue
Treated tissue
Organovo’s targeted market
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
Pharmaceutical and
Cosmetic area
(Big companies and
subcontractors)
23
Drug Discovery and Assays
04/11/2014
• Applications:
• Biocompatibility assays w/o animals (ISO)
• Improvement of existing models
Artificial skin Irritation testing
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
24
Cell Therapy & Tissue engineering
04/11/2014
• Facts: Cell Therapy
Cell therapy industry market
(autologous)
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
[Markets and Markets]
25
Cell Therapy & Tissue engineering
04/11/2014
• Facts: Cell Therapy
High potential for
Small defect repair
But spatial limitations
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
26
Cell Therapy & Tissue engineering
04/11/2014
• Raise cell therapy barrier of Large defect repairing
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
(= scaffold)
27
Cell Therapy & Tissue engineering
04/11/2014
Repairing large defects by combining
+
Stem Cells + Biomaterial Scaffold
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
= 1st step to bioprinting
+
28
Biotechnolgies & Bioprocess
04/11/2014
• Facts:
• More and more treatments using biomolecules instead of small
drugs: BioPharma / Biological Therapy (protein, peptide, antibody,
etc.) Produced with cells
• Very expensive products: cost reduction through production
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
[PharmPro]
29
Biotechnolgies & Bioprocess (Bioproduction)
04/11/2014
Application
• Biomolecule production: 2D 3D
• Pure and higher production
• Cost reduction, bigger productions
• Enlarge areas
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
[university of Virginia]
30
In vitro diagnostic and Research
04/11/2014
• Biomarker
• Biosensors
• Drug kinetic
• Pathogen reaction
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
biosensor
Blood brain barrier
31
Food & Agriculture
04/11/2014
• New food process?
Focus on food player with Life Science approach:
biomaterial ( e.g. Tissue engineering)
© sirris 2014 Charleroi | www.sirris.be | [email protected] |
Standards
Medical Device (MD)
MD Directive Regulation proposal
General MD standards (ISO 13485, 10993, …)
Specific standards for applications/material (e.g. ISO
13175 bone filling with Ca-P)
Faster and easier to label than Drugs
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 32
Magic Scaffold ------
Synthetic non-active
implant scaffold
Standards
Advanced therapy medicinal products – ATMP
Regulation 1394/2007
Drug like procedure
long clinical procedure (6-10 years, +post market)
heavy process constrains
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 33
Magic Cells
------
Standards
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 34
Magic Tissue
------
+
? ATMP Incubating cells
+ scaffold
Standards
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 35
Magic Cells
------
Magic Scaffold ------
Combined
during
surgery
ATMP
MD
Conclusion
04/11/2014 36 © sirris 2014 Charleroi | www.sirris.be | [email protected] |
Print biomaterial add cells
Print « exotic » biomaterial
validate it add cells
Print biomaterial and cells
Suggested steps to Bioprinting
innovation
Time to market
Bioprinting R&D players in Europe – few
04/11/2014 © sirris 2014 Charleroi | www.sirris.be | [email protected] | 37
…and others…
38
Sirris Additive Manufacturing: Contact
© sirris 2014 Charleroi | www.sirris.be | [email protected] | CENG 04/11/2014
Grégory NOLENS, PhD
Department of Additive Manufacturing
Mail: [email protected]
Mobile: +32 498 91 94 75
Skype: gnolens
SIRRIS
Rue Auguste Piccard, 20
B-6041 GOSSELIES BELGIUM
http://www.sirris.be
« Medical Additive Manufacturing & Rapid Prototyping »
« Sirris »